Clinical trial
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual…
NCT00267085 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00267085 |
|---|---|
| Title | Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease |
| Official title | A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | BreakThrough Therapeutics Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, Minimal Residual Disease |
| Intervention type | Biological |
| Interventions | Synthetic Tumor-Specific Breakpoint Peptide Vaccine |
| Enrollment | 11 |
| Start date | Dec 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Dec 20, 2005 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: